Latest Editas Medicine News & Updates

See the latest news and media coverage for Editas Medicine. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Editas Medicine

Gene editing company developing CRISPR medicines

editasmedicine.com
Headquarters
Cambridge, United States
Founded year
2013
Company type
Public company
Number of employees
200–500
Industry
Pharmaceuticals

Last updated

Latest news about Editas Medicine

In short: Editas Medicine shifted its focus to in vivo gene editing, reporting strong preclinical results for EDIT-401 despite major staff cuts.

Company announcements

Editas Medicine

Editas Medicine presents preclinical data for EDIT-401 reducing LDL-C

A single dose achieved >90% LDL-C reduction in non-human primates by upregulating LDLR.

Unlock all announcements with a

Media coverage

Yahoo Finance

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Editas narrows Q1 loss as costs fall, but revenues drop sharply. Pipeline focus shifts to in vivo gene editing and lead candidate EDIT-401.

Unlock all articles with a

Never miss news about Editas Medicine

Track Editas Medicine and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Editas Medicine competitors & trending companies

Browse news for competitors to Editas Medicine and other trending companies.